Strong maintenance data for olanzapine LAI

US drug major Eli Lilly's investigational olanzapine long-acting injection therapeutic showed a maintenance of treatment benefit in a late-stage trial.

In the 24-week double-blind maintenance study of 1,065 adult out-patients with schizophrenia, therapeutic doses of olanzapine LAI provided positive maintenance of treatment for up to six months.

Mean baseline-to-endpoint changes in Positive and Negative Syndrome total scores for patients treated with therapeutic olanzapine LAI doses differed significantly from those given the reference dose (p<0.001). Significant separation in PANSS total scores was seen between the therapeutic doses (150mg/two weeks, 300mg/two weeks, 405mg/four weeks) versus the reference dose (45mg/four weeks) starting at 11, three and two weeks, respectively, and maintained throughout the study (p<0.05).